Stella Lee, MD

Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.

As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.

Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.

Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.

As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.

Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.

Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.

As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.

Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.

Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.

Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.  

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.

Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.

Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.  

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common condition that significantly affects quality of life and results in more than a million surgeries a year worldwide.

Symptoms of CRSwNP often mimic allergic rhinitis or bacterial rhinosinusitis, and patients frequently receive inappropriate prescriptions for allergy medications and even multiple courses of antibiotics. But appropriate therapeutic intervention can help to relieve CRSwNP symptoms, prevent unnecessary pain and suffering, reduce disease progression, and potentially prevent the need for nasal polypectomy.

Dr Stella Lee from the University of Pittsburgh discusses the importance of early and accurate diagnosis of CRSwNP, which is now viewed as a long-term, systemic inflammatory disorder, as well as strategies to assess symptom and disease severity.  

---

Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .

Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.